SOPHiA DDM™ GIInger Genomic Integrity Solution

Unlock genomic insights with a universal key

pink dots icon

Empower your homologous recombination deficiency (HRD) analysis with our deep learning algorithm, GIInger™

SOPHiA DDM™ GIInger Genomic Integrity Solution accurately defines the genomic instability status of ovarian cancer samples. Designed to analyze whole genome sequencing data, it offers a flexible, in-house approach that complements your capture-based BRCA analysis for a complete HRD assessment.

Complementary to BRCA analysis

Seamlessly integrate GIInger™ into capture-based laboratory workflows, without the need for extra sample processing.

Low-pass whole genome sequencing (WGS)

Leverage coverage profiles from low-pass WGS data, requiring only ~1x coverage depth (minimum ~0.4x).

Robust, deep learning-based analysis

Reveal genomic instability status of FFPE ovarian cancer samples with the powerful GIInger™ algorithm.

Streamlined, technology-agnostic workflow

Save time with a FASTQ-to-report workflow, designed to be compatible with multiple wet lab and sequencing technologies.

Integrated tertiary analysis and reporting

Increase efficiency with evidence-based decision support and reporting features of OncoPortalPlus.

Collective intelligence

Access SOPHiA GENETICS Community, one of the largest knowledge-sharing networks of connected healthcare institutions.

Spice up your analysis with GIInger™

Current approaches to measuring genomic instability require deep genomic profiling data (>30x coverage), which can be costly and difficult to implement in routine analysis1.

To overcome these limitations, our expert team developed the GIInger™ deep learning algorithm, exclusively available on the SOPHiA DDMTM Platform. GIInger™ leverages data from low-pass whole genome sequencing profiles (~1x coverage) to produce the Genomic Integrity Index (GII), a predictive score of a sample’s genomic instability status.

pink dots icon

Add the missing piece to your workflow

Designed to be compatible with with different capture-based workflows, SOPHiA DDM™ GIInger Genomic Integrity Solution offers a universal approach to genomic analysis that seamlessly integrates with your existing  laboratory set-up with no impact on previous validation.

Adoption of our genomic applications is made easy with the SOPHiA DDM™ MaxCare Program, empowering teams to gain confidence in their results, establish workflow efficiency, meet quality standards, and ensure performance by offering comprehensive training and analytical performance assessment.

pink dots icon

Trust your data

High analytical concordance

In an equivalence study of 129 FFPE DNA samplesa from ovarian cancer tissue, the genomic instability status as determined by the SOPHiA DDM™ GIInger Genomic Integrity Solution (WGS workflow) was highly concordant with the status obtained with the SOPHiA DDM™ HRD Solution (targeted and whole genome sequencing workflow).

a50 ng, DQN>3, tumor content >30%. Samples were processed using SOPHiA  DDM™ HRD Solution library prep workflow and sequenced using Illumina® NovaSeq™ 6000. SOPHiA DDMTM GIInger Genomic Integrity Solution  is also verified for use with SOPHiA GENETICS™ Universal Library Prep.

Data on file.

pink dots icon

Expand identification of HRD-positive samples

Approximately 1 in 2 individuals with HRD-positive advanced ovarian cancer do not have a pathogenic BRCA mutation, however, they do show evidence of genomic instability or ‘scarring’2. 

Measuring genomic instability status can help identify samples that are BRCA wild-type but may still be sensitive to PARP inhibition2. By going beyond BRCA mutation detection, clinical researchers can maximize insights from genomic data and unlock the potential of precision oncology.

pink dots icon

What do our customers think?

The SOPHiA GENETICS team enabled a seamless integration of GIInger™ algorithm into our already validated in-house capture-based library preparation. We are now able to test the Genomic Integrity Index for all our ovarian cancer samples quickly, accurately, and seamlessly.

pink dots icon


Application type Dry lab solution (bioinformatics pipeline)
Sample type FFPE or FF ovarian cancer tissue
WGS coverage depth ~1x recommended (0.4x minimum)
Limit of detection 30% tumor content
Sequencer compatibility Illumina NextSeq® 550 and NovaSeq™ 6000
pink dots icon

Related genomic solutions

pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.


  1. Konstantinopoulos PA, et al. Cancer Discov. 2015;5(11):1137-54
  2. Colombo N, Ledermann JA. Ann Oncol. 2021;32(10):1300-3